ASL患者血清及脑脊液中MIP-1α和VEGF浓度的检测及临床意义

Clinical Significance of MIP-1α and VEGF Levels in Serum and CSF of ALS Patients

目的检测肌萎缩侧索硬化症(amyotrophic lateral sclerosis,ALS)患者血清及脑脊液(cerebrospinal fluid,CSF)中巨噬细胞炎性蛋白-1α(macrophage inflammatory protein-1 alpha,MIP-1α)和血管内皮生长因子(vascular endothelial growth factor,VEGF)浓度,研究血清和CSF中MIP-1α和VEGF浓度与ALS的临床相关性.方法收集2012年1月至2015年6月期间在铜川市矿务局中心医院就诊的ALS患者80例和紧张性头痛患者67例,采取其血清及脑脊液,采用ELISA法测定血清及脑脊液中的MIP-1α和VEGF浓度.结果 ALS患者血清及脑脊液中MIP-1α浓度均明显高于对照组,差异有统计学意义(P<0.05).ALS患者血清中VEGF浓度高于对照组,差异有统计学意义(P<0.05),ALS患者脑脊液中VEGF浓度高于对照组,差异无统计学意义(P>0.05).MIP-1α和VEGF浓度与ALS病程呈正相关性.长病程组的MIP-1α和VEGF浓度均大于短病程组(P<0.05).结论 MIP-1α和VEGF浓度升高可能表明在ALS代偿反应的激活,这反映MIP-1α和VEGF参与了肌萎缩侧索硬化的病理生理过程.VEGF和MIP-1α是具有预测和评估ALS潜在危害的生物标志物.

Objective Through the detection of MIP-1α and VEGF levels in serum and CSF of ALS patients, we evaluated the clinical value of MIP-1 and VEGF levels in ALS patients. Me thods A total of 80 patients with ALS were collected from Kuangwu Hospital of Tongchuanin from Jan, 2012 to Jun, 2015, and 67 patients with non-inflammation neurological diseases were chosen as control group. We obtained CSF and serum samples,and the MIP-1α and VEGF levels were measured by ELISA method. Re s ults The MIP-1α levels in serum and CSF of ALS patients were statistically and significantly higher than those in the control group（P〈0.05）.The VEGF levels in serum of ALS patients were statistically and significantly higher than those in the control group（P〈0.05）.The VEGF levels in CSF of ALS patients were not higher than those in the control group,statistically insignificant（P 〉0.05）.MIP-1 alpha and VEGF levels was positively correlated with ALS course. The MIP-1αand VEGF levels of the long duration group were greater than the short duration group（P 〈0.05）.Conclus ion The rising of MIP-1α and VEGF may indicate an activation of compensatory responses in ALS which suggested that MIP-1 alpha and VEGF are involved in the pathophysiology of amyotrophic lateral sclerosis. We propose that MIP-1α and VEGF may be a useful biomarker witha prognostic and evaluating potential for ALS.